Federal contracts
$1.6Kcommitted so far
4571045097!PURAPLY am (2X2) 4 sq cm
The Defense Department has committed $1.6K to Organogenesis so far. It runs until Mar 11, 2026.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ORGO · NASDAQ · Pharmaceutical Preparations
Organogenesis (ORGO) · oqro.io/stocks/ORGO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.7716−0.0176 (−2.23%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Organogenesis was filed in the last 90 days. The latest on record was on Jun 6, 2025.
Since 2018, Organogenesis insiders reported 72 open-market purchases and 77 sales on Forms 4 and 5, with purchases in 6 different years, most recently 2025.
No open-market sale by an insider of Organogenesis (ORGO) was filed with the SEC in the last 90 days.
No trade in Organogenesis (ORGO) was disclosed by a member of Congress in the last 12 months.
Organogenesis's next results are expected on Feb 24, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−84.9% (−$4.35) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $5.12 on Nov 20, 2025 to $0.7716 on Nov 20, 2026 (−84.9%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Canton, Ma.
Last 12 months
−84.9%
Market value
$104M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 15.6M shares sold short (11.6% of shares outstanding), +0.1% vs the previous count, 14.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$45.5M
−69.9% vs the same quarter a year earlier
Free cash flow, last 12 months
−$64K
This quarter −$20.1M, a year earlier $844K
Net debt
—
Debt —, cash $21.3M, at Sep 30, 2026
Net income, last 12 months
−$135M
Operating profit covers interest 30.7x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Revenue, fiscal 2025
$564M
+17.0% vs the year before
Net income, fiscal 2025
$37M
As reported in the annual filing
Shares outstanding
130M
As of Oct 30, 2026
In fiscal 2024 the company spent $25.5M buying back its own shares. Cash actually paid, from its cash-flow statement.
Federal contracts
4571045097!PURAPLY am (2X2) 4 sq cm
The Defense Department has committed $1.6K to Organogenesis so far. It runs until Mar 11, 2026.
Federal contracts
4571016149!PURAPLY am (2X2) 4 sq cm
The Defense Department has committed $1.6K to Organogenesis so far. It runs until Mar 9, 2026.
Federal contracts
4570154170!APLIGRAF
The Defense Department has committed $1.2K to Organogenesis so far. It runs until Dec 5, 2025.
Federal contracts
4570053804!DRSG WND 4.91X4.91CM puraply xt XCLR
The Defense Department has committed $8.5K to Organogenesis so far. It runs until Nov 24, 2025.
Federal contracts
4569995769!APLIGRAF
The Defense Department has committed $2.5K to Organogenesis so far. It runs until Nov 18, 2025.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Organogenesis reported 72 open-market purchases and 77 sales since 2018; purchases in 6 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $725K3×3 trades | $128K1×1 trade |
| 2024 | — | $3.24M11×11 trades |
| 2023 | — | $104K2×2 trades |
| 2022 | $114K7×7 trades | $10.3M29×29 trades |
| 2021 | $774K14×14 trades | $156M33×33 trades |
| 2020 | $22.5M18×18 trades | $900K1×1 trade |
| 2019 | $42.3M29×29 trades | — |
| 2018 | —1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Off-exchange trading: 45.8% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (21.7% on ATS, 24.1% with other brokers), close to its 26-week average of 45.6%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INTELLIGENT CROSS LLC (13.7%), UBS ATS (12.2%), INSTINCT X (10.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
No Schedule 13D or 13G filing on ORGO over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 26, 2026. Read the filing
+17% on the year before ($482M)
$0 the year before
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care and surgical and sports medicine markets. Our products have been shown through clinical and scientific studies to support and in some cases accelerate tissue healing and improve patient outcomes. We are advancing the standard of care in each phase of the healing process through multiple breakthroughs in tissue engineering and cell therapy. Our solutions address large and growing markets driven by aging demographics and increases in comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease.
And 16 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Feb 24, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
85%
60 of 71 insider purchases since 2018 came within 30 days after a results announcement
From Organogenesis's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Organogenesis's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
0 certified in FY2026 Q3, vs 0 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Latest annual report filed Feb 26, 2026, compared with the one filed Feb 27, 2025. Read the filing
We are not a party to any material legal proceedings. From time to time, we may become involved in litigation or other legal proceedings relating to claims arising from the ordinary course of business. These matters may include intellectual property, employment and other general claims.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Against the S&P 500 over the year
Since Nov 19, 2025, ORGO is down 85.0% and the index fund is up 4.1%: 89 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ORGO moves
Beta 1.3 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).